Covid-19：珊瑚

我们的珊瑚计划是第二代SARS-COV-2疫苗平台，旨在提供尖峰和其他SARS-COV-2 T细胞表位，我们认为这可以为更耐用的保护和更广泛的免疫力提供对SARS-COV-2的更广泛的免疫力变体。

Through a license agreement with the La Jolla Institute for Immunology (LJI), one of the leading global organizations dedicated to studying the immune system, we have access to validated SARS-CoV-2 antigens that have been identified through LJI’s studies of hundreds of patients recovering from COVID-19. Using such antigens, EDGE™ and vaccine platform technologies, Gritstone has developed novel vaccine candidates containing Spike (similar to first generation vaccines) but also additional viral antigens that we believe offer potential targets for broad T cell immunity. By targeting several viral antigens, some of which are highly conserved between viral strains (such as SARS and SARS-CoV-2), our vaccine may have pan-coronavirus potential to protect against both current and future coronavirus pandemics.

Gritstone进行了临床前和临床研究，表明我们的SARS-COV-2疫苗可以诱导针对峰值蛋白的显着和持续水平的中和T细胞，以及针对Spike以外多个病毒基因的表位的广泛T细胞反应。

我们已收到该法案和梅琳达·盖茨基金会的赠款，以支持对疫苗的临床前评估。美国国立卫生研究院的一部分，国家过敏和传染病研究所（NIAID）支持通过传染病临床研究联盟（IDCRC）进行的1期临床试验。我们还与《流行病准备联盟》（CEPI）达成了一项协议，该联盟提供了资金，以对南非的Gritstone疫苗候选者进行1期临床试验。

学到更多